The CE Mark allows the system to be sold throughout the European Union, and follows the product’s US FDA 510k clearance, received in July 2011.
The Group has also secured the first UK pilot deployment of SensiumVitals with Spire Healthcare (‘Spire’), a leading UK provider of private healthcare. The pilot will start in a Spire Healthcare hospital in early 2014. Spire has 38 hospitals across the country. A similar pilot, conducted earlier this year in the med-surgical unit at St John’s Health Center, Santa Monica, California, provided clear evidence of both the clinical and economic benefits of the system.
Separately, Toumaz has also announced a new distribution agreement with NantHealth for SensiumVitals in North America, including its first commercial order and confirmation of its first pilot deployment in an A&E department at Hurley Medical Center, Flint, Michigan
”Results from the SensiumVitals pilot in North America have provided clear evidence that the system can shorten hospital stays and reduce healthcare costs. We are confident that similar results will be achieved in the UK and the rest of Europe”, said Anthony Sethill, CEO of Toumaz.
Visit Toumaz at www.toumaz.com